Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7327
Source ID: NCT03286751
Associated Drug: Ly900014
Title: A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT03286751/results
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: LY900014|DRUG: Insulin Lispro
Outcome Measures: Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC), Pharmacokinetics: Insulin Lispro Area Under the Concentration Curve From Time Zero to 10 Hours Post Dose \[AUC(0-10h)\], Day 1: Pre-dose, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 90, 120, 150, 180, 210, 240, 300, 360, 420, 480, 540, and 600 minutes post-dose | Secondary: Glucodynamics: Total Amount of Glucose Infused (Gtot), Glucodynamics: Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp, Day 1: Every minute starting from the pre-dose and throughout the duration of the clamp until 10 hours post-dose
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 42
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
Start Date: 2017-10-13
Completion Date: 2018-02-06
Results First Posted: 2020-05-01
Last Update Posted: 2020-05-01
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, 55116, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, 41460, Germany
URL: https://clinicaltrials.gov/show/NCT03286751